Alnylam Pharmaceuticals, Inc. (ALNY)
236.06
-0.16
(-0.07%)
USD |
NASDAQ |
Aug 24, 16:00
237.08
+1.02
(+0.43%)
After-Hours: 20:00
Alnylam Pharmaceuticals EPS Diluted (Quarterly) : 1.207 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.207 |
| March 31, 2026 | 1.508 |
| December 31, 2025 | 1.368 |
| September 30, 2025 | 1.840 |
| June 30, 2025 | -0.5529 |
| March 31, 2025 | -0.1407 |
| December 31, 2024 | -0.6487 |
| September 30, 2024 | -0.8676 |
| June 30, 2024 | -0.1333 |
| March 31, 2024 | -0.5227 |
| December 31, 2023 | -1.098 |
| September 30, 2023 | 1.152 |
| June 30, 2023 | -2.214 |
| March 31, 2023 | -1.403 |
| December 31, 2022 | -1.683 |
| September 30, 2022 | -3.323 |
| June 30, 2022 | -2.295 |
| March 31, 2022 | -1.996 |
| December 31, 2021 | -2.158 |
| September 30, 2021 | -1.717 |
| June 30, 2021 | -1.610 |
| March 31, 2021 | -1.711 |
| December 31, 2020 | -2.094 |
| September 30, 2020 | -2.184 |
| June 30, 2020 | -1.560 |
| Date | Value |
|---|---|
| March 31, 2020 | -1.616 |
| December 31, 2019 | -2.471 |
| September 30, 2019 | -1.918 |
| June 30, 2019 | -2.022 |
| March 31, 2019 | -1.726 |
| December 31, 2018 | -2.092 |
| September 30, 2018 | -2.434 |
| June 30, 2018 | -1.627 |
| March 31, 2018 | -1.412 |
| December 31, 2017 | -1.48 |
| September 30, 2017 | -1.34 |
| June 30, 2017 | -1.344 |
| March 31, 2017 | -1.247 |
| December 31, 2016 | -1.32 |
| September 30, 2016 | -1.21 |
| June 30, 2016 | -1.05 |
| March 31, 2016 | -1.21 |
| December 31, 2015 | -1.07 |
| September 30, 2015 | -0.91 |
| June 30, 2015 | -0.85 |
| March 31, 2015 | -0.62 |
| December 31, 2014 | -0.28 |
| September 30, 2014 | -0.58 |
| June 30, 2014 | -0.58 |
| March 31, 2014 | -3.70 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | -0.6931 |
| Regeneron Pharmaceuticals, Inc. | 12.23 |
| Vertex Pharmaceuticals, Inc. | 4.310 |
| BridgeBio Pharma, Inc. | -0.7775 |
| Pfizer Inc. | -0.0435 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 164.49M |
| Revenue (Quarterly) | 1.291B |
| Total Expenses (Quarterly) | 1.126B |
| Enterprise Value | 31.27B |
| Gross Profit Margin (Quarterly) | 76.88% |
| Profit Margin (Quarterly) | 12.74% |
| Earnings Yield | 2.51% |
| Operating Earnings Yield | 3.08% |
| Normalized Earnings Yield | 2.438 |